Govt Job for Ph.D, M.Pharm, M.Sc as Research Associate at PGIMER

The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage.

A Research Associate is required in the research project entitled, “Development of personalized radiation treatment regime using Radio-genomics based radiation toxicity prediction model in Head Neck Squamous Cell Carcinoma (HNSCC)” funded by ICMR, New Delhi in Department of Biochemistry, PGIMER, Chandigarh.

Post : Research Associate

Essential qualification :PhD / MD / MS or Equivalent degree or having 3 years of research and/or teaching with at least one research paper in Science Citation Indexed (SCI) journal
Age : As per ICMR rules (Relaxation will be given to women/SC/ST/OBC/PWD candidates as per rules)
Desirable : Experience in NGS data analysis and Statistical methods for developing risk prediction models

Salary/Stipend : Rs. 47,000/- + HRA @16% i.e. Rs. 7,520 p.m
Tenure : Initially for 1 year to be extended till the tenure of the project subject to the performance of the candidate

Interested candidates are requested to send detailed CV to the undersigned through e-mail ID: Iab320pgi@gmail.com.
Online interview : Shortlisted candidates will be intimated through e-mail. Interview will be on Zoom/Google meet platform

Last date of submission of CV :June 9, 2021

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March